{"type":"trials","record":{"id":41444,"source_id":"clinicaltrials-gov","external_id":"NCT07531927","title":"Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy","brief_summary":"Geographic atrophy (GA) is a progressive eye disease that causes the degeneration of the retinal cells, particularly in the macula, leading to vision loss. The goal of this pilot study is to evaluate the safety and the effectiveness of transcorneal electrical stimulation (TES) therapy with the OkuStim 2 System in patients with geographic atrophy (GA). Researchers will compare the effects of two different electrical stimuli with a placebo to see if the stimuli are safe and can slow down the progression of the disease. Participants will be randomly assigned to one of these three groups: * TES-treatment with a rectangular stimulus * TES-treatment with a repetitive ramp stimulus * Placebo (sham) treatment Participants will apply the therapy at home, once a week for 30 minutes each over a duration of 1 year.","overall_status":"Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Okuvision GmbH","enrollment":70,"countries":["Germany"],"start_date":"2026-05-05","completion_date":"2028-06-01","last_update_date":"2026-07-28","source_url":"https://clinicaltrials.gov/study/NCT07531927","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"TES-GAP","age_range":"60 Years","comparator":null,"organization":"Okuvision GmbH","interventions":["Transcorneal electrical stimulation (TES) with the OkuStim 2 System"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Safety of TES therapy in GA — From enrolment until the end of the study for the individual participant at 52 weeks","Effects of TES therapy with two different stimulus waveforms on the progression of GA lesion areas — At 12 months and a…","Effects of TES therapy with two different stimulus waveforms on structural changes in retinal layers — At 12 months and…","Effects of TES therapy with two different stimulus waveforms on functional changes in the border zone of GA areas — At…","Effects of TES therapy with two different stimulus waveforms on visual acuity under normal luminance conditions — At 12…","Effects of TES therapy with two different stimulus waveforms on visual acuity under low-luminance conditions — At 12 mo…","Effects of TES therapy with two different stimulus waveforms on patient-reported outcomes regarding the impact on daily…","Effects of TES therapy with two different stimulus waveforms on patient-reported outcome regarding the applicability of…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","source_has_results":false},"controlled_terms":["Geographic Atrophy Secondary to Age-related Macular Degeneration","Transcorneal electrical stimulation (TES) with the OkuStim 2 System"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07531927","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-05-05 to 2028-06-01","comparator":null,"confidence":"structured-source","population":"ALL · 60 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.813Z","intervention":["Transcorneal electrical stimulation (TES) with the OkuStim 2 System"],"participants":70,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Safety of TES therapy in GA — From enrolment until the end of the study for the individual participant at 52 weeks","Effects of TES therapy with two different stimulus waveforms on the progression of GA lesion areas — At 12 months and a…","Effects of TES therapy with two different stimulus waveforms on structural changes in retinal layers — At 12 months and…","Effects of TES therapy with two different stimulus waveforms on functional changes in the border zone of GA areas — At…","Effects of TES therapy with two different stimulus waveforms on visual acuity under normal luminance conditions — At 12…","Effects of TES therapy with two different stimulus waveforms on visual acuity under low-luminance conditions — At 12 mo…","Effects of TES therapy with two different stimulus waveforms on patient-reported outcomes regarding the impact on daily…","Effects of TES therapy with two different stimulus waveforms on patient-reported outcome regarding the applicability of…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41444","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}